Colorectal cancer affects many lives, and finding better treatments is crucial. A new study is looking at SHR-8068 injection combined with other therapies to see if it can improve outcomes for patients. The focus is on safety, tolerability, and effectiveness, which are key factors in treatment success. With an estimated 200 participants, this research could lead to important advancements in how we treat colorectal cancer. If successful, it may offer hope to those battling this challenging illness, potentially leading to better survival rates and quality of life.
Could a new treatment help fight colorectal cancer more effectively?
Plain Language Summary
What this means for you:
SHR-8068 injection may offer new hope for colorectal cancer patients when combined with existing therapies. What this means for you:
SHR-8068 injection may offer new hope for colorectal cancer patients when combined with existing therapies. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Colorectal Cancer
Intervention(s): SHR-8068 Injection (DRUG), Adebrelimab Injection (DRUG), Bevacizumab Injection (DRUG)
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.
Primary Outcome(s): Pathological Complete Response (pCR); Progression Free Survival (PFS)
Enrollment: 200 (ESTIMATED)
Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Start: 2025-07-22 | Primary Completion: 2031-10